Organon Co (OGN)

Apr 18, 2025

(OGN) Technical Pivots with Risk Controls - news.stocktradersdaily.com

Apr 18, 2025

Apr 16, 2025

Ganirelix Market Is Booming Worldwide 2025-2032 | Organon & Co.,Merck & Co., Inc.,Ferring Pharmaceuticals - openPR.com

Apr 16, 2025

Apr 16, 2025

Organon stock hits 52-week low at $10.92 amid market challenges By Investing.com - Investing.com South Africa

Apr 16, 2025

Apr 16, 2025

Organon stock hits 52-week low at $10.92 amid market challenges - Investing.com Australia

Apr 16, 2025

Apr 15, 2025

Organon expands board with new director from Takeda - Investing.com

Apr 15, 2025

Apr 15, 2025

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors - Bluefield Daily Telegraph

Apr 15, 2025

Apr 15, 2025

Takeda President Ramona Sequeira Joins Organon Board: Major Win for Women's Health Giant - Stock Titan

Apr 15, 2025

Apr 15, 2025

Organon & CoExpects $6 Million Milestone Expense In Q1 2025 - marketscreener.com

Apr 15, 2025

Apr 15, 2025

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025 - Bluefield Daily Telegraph

Apr 15, 2025

Apr 15, 2025

Organon Earnings Alert: Q1 2025 Results Coming May 1 with $6M Milestone Expenses - Stock Titan

Apr 15, 2025

Apr 14, 2025

Organon (OGN) Laps the Stock Market: Here's Why - Yahoo Finance

Apr 14, 2025

Apr 14, 2025

EU regulator reviews anti-baldness drugs over concerns of suicidal thoughts - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Organon's NDURVA Cream Gets Health Canada Approval for Plaque Psoriasis Treatment - marketscreener.com

Apr 14, 2025

Apr 14, 2025

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - Yahoo Finance

Apr 14, 2025

Apr 12, 2025

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11 - 뉴스와이어

Apr 12, 2025

Apr 10, 2025

Organon's Ba2 CFR affirmed by Moody's, outlook revised to negative - Investing.com Australia

Apr 10, 2025

Apr 10, 2025

Organon’s Ba2 CFR affirmed by Moody’s, outlook revised to negative - Investing.com Canada

Apr 10, 2025

Apr 10, 2025

Strength Seen in Organon (OGN): Can Its 8.5% Jump Turn into More Strength? - Nasdaq

Apr 10, 2025

Apr 10, 2025

Organon (OGN) Sees Flat Revenue, Downgraded Full-Year Outlook - GuruFocus

Apr 10, 2025

Apr 08, 2025

Q4 Earnings Roundup: Organon (NYSE:OGN) And The Rest Of The Branded Pharmaceuticals Segment - Yahoo Finance

Apr 08, 2025

Apr 07, 2025

Organon Enters Oversold Territory - Nasdaq

Apr 07, 2025

Apr 07, 2025

Organon (OGN): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance

Apr 07, 2025

Apr 05, 2025

Organon (OGN): Company Profile, Stock Price, News, Rankings - Fortune

Apr 05, 2025

Apr 05, 2025

Organon stock hits 52-week low at $13.84 amid market challenges - Investing.com Canada

Apr 05, 2025

Apr 04, 2025

Organon stock hits 52-week low at $13.84 amid market challenges By Investing.com - Investing.com South Africa

Apr 04, 2025

Apr 03, 2025

Organon (OGN) Stock Moves -1.83%: What You Should Know - Yahoo Finance

Apr 03, 2025

Apr 02, 2025

Why Organon (OGN) Could Beat Earnings Estimates Again - Yahoo Finance

Apr 02, 2025

Apr 02, 2025

Organon acquires Actemra biosimilar’s US rights from Biogen - Pharmaceutical Technology

Apr 02, 2025

Apr 02, 2025

Organon Looks To Tap Tocilizumab Potential Following Biogen Acquisition - insights.citeline.com

Apr 02, 2025

Apr 01, 2025

Organon acquires US rights to arthritis biosimilar TOFIDENCE By Investing.com - Investing.com South Africa

Apr 01, 2025

Apr 01, 2025

Organon Expands Biosimilar Portfolio With Tofidence Acquisition - Managed Healthcare Executive

Apr 01, 2025

Apr 01, 2025

Organon Acquires TOFIDENCE - citybiz

Apr 01, 2025

Apr 01, 2025

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock - Yahoo Finance

Apr 01, 2025

Apr 01, 2025

Organon Acquires Tofidence for Intravenous Infusion in US - MarketScreener

Apr 01, 2025

Apr 01, 2025

Organon buys rights to Biogen’s biosimilar targeting Roche’s Actemra - Seeking Alpha

Apr 01, 2025

Apr 01, 2025

Organon acquires rights for Tofidence from Biogen - TipRanks

Apr 01, 2025

Apr 01, 2025

Organon acquires US rights to arthritis biosimilar TOFIDENCE - Investing.com

Apr 01, 2025

Apr 01, 2025

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S. - Bluefield Daily Telegraph

Apr 01, 2025

Apr 01, 2025

Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal - Stock Titan

Apr 01, 2025

Mar 31, 2025

Natixis Advisors LLC Decreases Stock Holdings in Organon & Co. (NYSE:OGN) - MarketBeat

Mar 31, 2025

Mar 28, 2025

Organon (OGN) Stock Moves -0.34%: What You Should Know - Yahoo Finance

Mar 28, 2025

Mar 28, 2025

Organon, Henlius Say EMA Validates Marketing Authorization Application for Proposed Breast Cancer Drug - MarketScreener

Mar 28, 2025

Mar 28, 2025

European Medicines Agency (EMA) Validates Henlius And Organon Filing For Perjeta® (Pertuzumab) Biosimilar Candidate HLX11 - MarketScreener

Mar 28, 2025

Mar 28, 2025

Organon, Shanghai Henlius Biotech: EMA validates MAA for HLX11 - TipRanks

Mar 28, 2025

Mar 28, 2025

Major Win: Organon's Breast Cancer Drug Gets Critical EMA Validation After Trial Success - Stock Titan

Mar 28, 2025

Mar 27, 2025

Organon (OGN) Falls More Steeply Than Broader Market: What Investors Need to Know - Yahoo Finance

Mar 27, 2025

Mar 27, 2025

Organon & Co. (OGN): A Deep Value Play with a 35.96% Upside Potential and an Attractive 7.61% Dividend Yield - DirectorsTalk Interviews

Mar 27, 2025